Improving outcomes for high‐risk ALL: Translating new discoveries into clinical care
- 15 February 2011
- journal article
- review article
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 56 (6) , 984-993
Abstract
High‐risk (HR) acute lymphoblastic leukemia (ALL) remains one of the greatest challenges in pediatric oncology. Relapsed ALL is a leading cause of death in young people, and further improvements in outcome will required the development of therapeutic approaches directed against rational therapeutic targets, as escalation of the intensity of existing therapies is limited by toxicity. This review summarizes advances in the biology and treatment of HR and relapsed ALL presented at a symposium at the 2010 American Society for Pediatric Hematology and Oncology Annual Meeting. Analysis of large patient cohorts has identified several factors associated with HR of relapse including older age, T‐lineage disease, and persisting minimal residual disease (MRD) early in therapy. As the results of salvage therapy remain poor, new treatment approaches are needed. BCR‐ABL1‐positive (Ph+) ALL has historically had a very poor outcome, but recent studies have demonstrated the impressive improvements in treatment outcome with the use of tyrosine kinase inhibitors (TKIs). High‐resolution genomic profiling of genetic alterations and gene expression has revolutionized our understanding of the genetic basis of ALL, and has identified several alterations associated with poor outcome, including mutations of the lymphoid transcription factor gene IKZF1 (IKAROS), activating mutations of Janus kinases, and rearrangement of the lymphoid cytokine receptor gene CRLF2. These data indicated that the genetic basis of HR‐ALL is multifactorial, and have also provided a new potential therapeutic option directed at JAK inhibition. Pediatr Blood Cancer 2011;56:984–993.Keywords
This publication has 93 references indexed in Scilit:
- Long-term results of the children's cancer group studies for childhood acute lymphoblastic leukemia 1983–2002: A Children's Oncology Group ReportLeukemia, 2009
- Rearrangement of CRLF2 in B-progenitor– and Down syndrome–associated acute lymphoblastic leukemiaNature Genetics, 2009
- Treating Childhood Acute Lymphoblastic Leukemia without Cranial IrradiationNew England Journal of Medicine, 2009
- JAK mutations in high-risk childhood acute lymphoblastic leukemiaProceedings of the National Academy of Sciences, 2009
- A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification studyThe Lancet Oncology, 2009
- Deletion ofIKZF1and Prognosis in Acute Lymphoblastic LeukemiaNew England Journal of Medicine, 2009
- Single-Cell Profiling Identifies Aberrant STAT5 Activation in Myeloid Malignancies with Specific Clinical and Biologic CorrelatesCancer Cell, 2008
- Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's Oncology Group studyLeukemia, 2008
- Role of JAK2 in the pathogenesis and therapy of myeloproliferative disordersNature Reviews Cancer, 2007
- Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid LeukemiaNew England Journal of Medicine, 2003